Frequent MAGE mutations in human melanoma

Caballero, Otavia L.;Zhao, Qi;Rimoldi, Donata;Stevenson, Brian J.;Simpson, Andrew J.;et.al.
(2010) PLoS One — Vol. 5, n° 9, p. e12773 (2010)

Files

pdfdocument.pdf
  • Open Access
  • Adobe PDF
  • 241.1 KB

Details

Authors
  • Caballero, Otavia L.LICR NY
    Author
  • Zhao, QiJ. Craig Venter Institute, Rockville, Maryland, USA
    Author
  • Rimoldi, DonataLICR Lausanne
    Author
  • Stevenson, Brian J.LICR Lausanne
    Author
  • Brasseur, FrancisUCLouvain
    Author
  • Author
  • Simpson, Andrew J.LICR NY
    Author
Show more
Abstract
BACKGROUND: Cancer/testis (CT) genes are expressed only in the germ line and certain tumors and are most frequently located on the X-chromosome (the CT-X genes). Amongst the best studied CT-X genes are those encoding several MAGE protein families. The function of MAGE proteins is not well understood, but several have been shown to potentially influence the tumorigenic phenotype. METHODOLOGY/PRINCIPAL FINDINGS: We undertook a mutational analysis of coding regions of four CT-X MAGE genes, MAGEA1, MAGEA4, MAGEC1, MAGEC2 and the ubiquitously expressed MAGEE1 in human melanoma samples. We first examined cell lines established from tumors and matching blood samples from 27 melanoma patients. We found that melanoma cell lines from 37% of patients contained at least one mutated MAGE gene. The frequency of mutations in the coding regions of individual MAGE genes varied from 3.7% for MAGEA1 and MAGEA4 to 14.8% for MAGEC2. We also examined 111 fresh melanoma samples collected from 86 patients. In this case, samples from 32% of the patients exhibited mutations in one or more MAGE genes with the frequency of mutations in individual MAGE genes ranging from 6% in MAGEA1 to 16% in MAGEC1. SIGNIFICANCE: These results demonstrate for the first time that the MAGE gene family is frequently mutated in melanoma.
Affiliations
  • LICR NYMemorial Sloan-Kettering Cancer Center
  • J. Craig Venter Institute, Rockville, Maryland, USAJ. Craig Venter Institute, Rockville, Maryland, USA
  • LICR LausanneLICR Lausanne
  • LICR MelbourneMelbourne Centre for Clinical Sciences, Austin Health, Heidelberg, Victoria, Australie
  • LICR Ltd, Oxford Branch, Headington, Oxford, UKNuffield Department of Clinical Medicine, University of Oxford
  • LICR NY & Ludwig Center for Cancer Immunotherapy, New York, USAMemorial Sloan-Kettering Cancer Center & Department of Medicine
  • Memorial Sloan-Kettering Cancer Center, New York, USADepartment of Medicine and Ludwig Center for Cancer Immunotherapy
  • Oregon Health & Science University, Portland, Oregon, USADivision of Gynecologic Oncology and the Knight Cancer Institute
  • Roswell Park Cancer Institute, Buffalo, New York, USADepartment of Gynecological Oncology and Center for Immunotherapy
  • LICR NYLICR NY

Citations

Caballero, O. L., Zhao, Q., Rimoldi, D., Stevenson, B. J., Svobodova, S., Devalle, S., Röhrig, U. F., Pagotto, A., Michielin, O., Speiser, D., Wolchok, J. D., Liu, C., Pejovic, T., Odunsi, K., Brasseur, F., Van den Eynde, B., Old, L. J., Lu, X., Cebon, J., et al. (2010). Frequent MAGE mutations in human melanoma. PLoS One, 5(9), e12773. https://doi.org/10.1371/journal.pone.0012773 (Original work published 2010)